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Objectives: Osteoarthritis (OA) is a degenerative disease with a subset of patients experiencing joint
inﬂammation, but C-reactive protein (CRP) has shown limited use in OA as a diagnostic marker. The aim
was to identify subpopulations of patients with high or low levels of acute (high sensitive CRP (hsCRP))
and/or matrix metalloproteinase (MMP) derived inﬂammation (CRPM) and investigate the sub-
populations’ association with biomarkers of collagen degradation and KellgreneLawrence (KL) score.
Methods: hsCRP, CRPM and MMP-degraded type I, II and III collagen (type I collagen degraded by MMP
(C1M), type II collagen degraded by MMP (C2M) and type III collagen degraded by MMP (C3M)) were
quantiﬁed by enzyme linked immunosorbent assays (ELISA) in serum of 342 patients with symptomatic
knee OA of which 60 underwent total knee replacement (TKR). KL was obtained. Patients were divided
into quartiles by hsCRP and CRPM levels, where Q1 and Q4 were low or high in both. The biomarker
levels of healthy adults provided in the ELISA kits were used as reference level.
Results: hsCRP was elevated in TKR (5.9(3.6e8.2 95% conﬁdence interval (CI)) mg/mL) compared to
reference level (3 mg/mL), while CRPM was highly elevated with OA independent of KL (10e14 ng/mL)
compared to reference level (5 ng/mL). Q4 had higher KL than Q1 (P < 0.001), Q2 (P ¼ 0.017) and Q3
(P < 0.001). C1M, C2M and C3M were lowest in Q1. C1M was elevated in Q3 compared to Q2 (P < 0.001),
whereas C3M was lower (P ¼ 0.019).
Conclusion: A bigger proportion of patients were elevated in CRPM compared to hsCRP, indicating MMP-
derived inﬂammation as a component of OA. Moreover, the levels of MMP-degraded collagens differed
between the subgroups segregated by inﬂammation, indicating distinctively different subpopulation
selected by inﬂammation.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a degenerative joint disease driven by
continued and irreversible deterioration of the joint with a mild
inﬂammatory component1. One of the main challenges of the dis-
ease is the lack of effective treatment for both symptoms and joint
deterioration. A reason for the limited success could be attributed
to the heterogeneity of the of the OA population. Arthroscopic
evaluations of knee joints show that about 25% of subjects with
knee OA have inﬂamed synovial tissue (synovitis) associated withA.S. Siebuhr, Rheumatology,
Hovedgade 207, 2730 Herlev,
ebuhr).
s Research Society International. Psymptomatic OA (i.e., joint swelling, pain and joint stiffness): These
patients have increased risk of radiographic progression2e4.
The acute phase protein C-reactive protein (CRP) is an important
inﬂammatory regulator and measurement of circulating CRP is
widely used as a diagnostic tool in acute inﬂammatory diseases.
However, CRP has shown limited value in monitoring the low, but
elevated level of inﬂammation in OA5,6. CRP is produced in the liver
upon acutely elevated levels of circulating pro-inﬂammatory cyto-
kines, such as interleukin (IL) 67.When CRP is released from the liver,
it binds to its receptors and is speculated to accumulate in the
inﬂamed tissue.Here it is graduallydegradedby the increased level of
proteolytical enzymes and released as fragments into the circula-
tion8. One of these fragments is detected in a recently developed
enzyme linked immunosorbent assays (ELISA) called CRPM (MMP-
dependt degradation of CRP)9. As CRPM solely measures a post-ublished by Elsevier Ltd. All rights reserved.
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that it is a measure of chronic inﬂammation in contrast to the acute
phase measure of circulating CRP.
OA involves a cascade of catabolic events that ultimately leads to
an imbalance in tissue turnover. The exact aetiology is not fully
elucidated, though it is recognized that destruction of articular
cartilage, osteophyte formation and synovitis are hallmarks of the
disease4,10. These hallmarks can be described as structural changes
of the extracellular matrix driven by an up-regulation of inﬂam-
matory cytokines and proteolytic enzymes11,12. This results in the
loss of tissue integrity and release of protease mediated degrada-
tion fragments of extracellular matrix proteins that can be assessed
by an increasing number of immuno-assays investigating structural
integrity, such as type I collagen degraded by matrix metal-
loproteinase (MMP) (C1M), type II collagen degraded by MMP
(C2M), type III collagen degraded by MMP (C3M), CTX-I, CTX-II,
COMP and PIIANP13e18.
Synovitis involves expansion of resident synoviocytes and
inﬁltration of mononuclear cells resulting in an increase in cell
number and thickening of the synovial membrane due to ﬁbro-
genesis19. Fibrogenesis includes the increased expression of type III
collagen and MMPs; consequently, there is an elevated turnover of
the type III collagen followed by the release of MMP generated
protein fragments, such as C3M20. Type I collagen, the most
abundant structural collagen of the human body, is another
collagen of the connective tissue, including the synovial membrane.
MMP-mediated degradation of type I collagen results in the release
of neo-epitopes, such as ICTP21 and C1M18. These fragments are
destroyed by cathepsin K and might therefore not originate from
bone, hence these fragments identiﬁes a different type I collagen
degradation than CTX-I21. Type II collagen is the main extracellular
matrix protein of cartilage and loss of type II collagen is widely
believed to be a surrogate marker for cartilage erosion in arthritic
diseases1,13,14,17,22,23. Protein fragments generated by MMP-
degradation of type II collagen and the use of these protein frag-
ments have been well described in clinical trials15,22. Examples of
protein fragment biomarkers of MMP-mediated type II collagen
are; (1) helical fragments (C2M) measured in serum17; (2) C-ter-
minal telopeptide (CTX-II) measured in urine23e25; and (3) the ¼
fragments (C2C, TIINE) measured in urine26.
Not all OA patients experience joint inﬂammation or synovial
ﬁbrogenesis, illustrating theheterogeneityofOA3,4.We speculate that
a subset of patients may beneﬁt from anti-inﬂammatory treatments
alreadyused inother rheumaticdiseases, suchas rheumatoidarthritis
(RA) and ankylosing spondylitis (AS). However, since only a subset of
patient experience chronic inﬂammation it may be important to
segregate patient into those that will beneﬁt from an anti-
inﬂammatory treatment and those that will not. The aims of the
presented study were to (1) identify and segregate an OA population
according the level of acute and/or MMP-derived inﬂammation,
measured by serum high sensitive (hs) CRP and serum CRPM,
respectively and (2) describe each of these subgroups based on the
serumlevelsof the collagendegradationmarkersC1M,C2MandC3M.Patients and methods
The studies
We combined two cross-sectional studies initiated to investi-
gate the pain related to knee OA: The C4Pain study (n ¼ 282,
Videnskabsetisk komité Region Nordjylland (VEK); The Ethical
Committee of North Jutland no.: N-20100094; www.dnvk.dk/
GodkendteProjekter.aspx) and HTF-Synovitis study (n ¼ 60, VEK
no.: N-20110031).In the C4Pain study the OA population was recruited from
the patient databases of Center of Clinical and Basic Research
(CCBR) and C4Pain (Aalborg, Denmark), from Frederikshavn
Hospital (Frederikshavn, Denmark) and from advertisements in the
local newspapers of Northern Jutland. Males and females between
18 and 80 years of age with symptomatic idiopathic (primary) knee
OA according to American College of Rheumatology criteria were
included. Subjects were excluded if they had secondary OA, psy-
chiatric conditions, pregnancy, previous drug or alcohol abuse,
previous neurological or concomitant musculoskeletal disorders
and patients unable to abstain from analgesic medication for at
least 72 h prior to the knee pain assessment. A control group with
no pain (24 h maximal visual analogue scale (VAS) < 10) was
included based on the same inclusion and exclusion criteria. Four
equally sized groups based on pain were included categorized ac-
cording to 24-h maximal VAS rated from 0 to 100 (VAS 0e9; VAS
10e39; VAS 40e69; VAS 70e100). Two plane X-ray examination in
standing position was performed and KellgreneLawrence (KL)
score obtained, if a KL score had not been obtainedwithin 6months
before inclusion. However, eight patients did not have a KL score
recorded. Patients had KL scores ranging from 0 to 4.
The OA population of the HTF-Synovitis study was recruited,
when they were referred to total knee replacement (TKR). The
study followed the same study protocol as the C4Pain study, hence
the same inclusion and exclusion criteria were used. Patients in the
HTF-Synovitis study had OA diagnosed based on increased pain
level, decreased mobility and radiological assessment. All but one
had KL score recorded and two patients had a KL score of 3 and the
rest had a KL score of 4.
Serum was collected upon overnight (ON) fasting prior to sur-
gery or during consultation in both studies. Information on already
administered treatments was not collected during this study and
the effect was therefore not assessed. A total of 342 patients were
included in the combined cross-sectional study. 52% of the popu-
lationwas women, the mean age was 65.3 (95% conﬁdence interval
(CI): 64.4e66.2) years and the mean disease duration was 10.3
(9.3e11.3) years. Mean bodymass index (BMI) was 28.3 (27.9e28.8)
and they had a mean KL score of 2.3 (2.2e2.5). The mean pain in-
tensity by VAS scoring was 44.2 (41.0e47.5). The level of the
inﬂammation markers high sensitive CRP (hsCRP) and CRPM were
3.4 (2.8e4.1) mg/mL and 11.2 (10.8e11.6) ng/mL, respectively. The
level of the tissue integrity markers C1M, C2M and C3M were 57.5
(53.8e61.1), 0.34 (0.32e0.35), and 19.2 (18.5e19.9) ng/mL,
respectively.
The studies were approved by The Ethical Committee of
Northern Jutland. They were conducted accordingly to the Principal
of Good Clinical Practice and according to the Declaration of Hel-
sinki. All patients provided written informed consent.
Biomarkers
ELISA based on neo-epitopes were used to quantify structural
integrity. A neo-epitope is a speciﬁc amino acid sequence that is
speciﬁc of a cleavage of a protein by a certain protease. The neo-
epitope ELISAs used were MMP-derived fragments of proteins.
We quantiﬁed MMP-derived degradation of type I, II and III
collagen (C1M, C2M and C3M, respectively), as well as an MMP-
derived degradation fragment of CRP (CRPM). All these neo-
epitope ELISAs are based on monoclonal antibodies and are
competitive ELISAs produced at Nordic Bioscience.
C1M is previously described and is detecting an MMP-2, -9, and
-13-generated fragment of type I collagen, which is destroyed by
Cathepsin K. The assay targets the neo-epitope at amino acid po-
sition 755e764 (GSPGKDGVRGY; the arrow indicates cleavage site)
and does not recognise intact or other collagen, as well as cleavages
Table I
Technical performance of biomarker assays used, including reference levels of healthy young adult and RA patients
Measuring range IC50 Inter-assay (%) Intra-assay (%) Reference value of
healthy young adults
Reference value of
RA patients2
hsCRP (mg/mL) 0.2e10 n.a. <5 n.a. <3 >10
CRPM (ng/ml) 0.5e19 3.58 14.4 11.9 4.82 [4.43e5.61] 17.7 [16.4e19.0]
C1M (ng/ml) 1e363 68.9 9.94 6.07 50.9 [41.5e60.3] 109 [99.0e119]
C2M (ng/ml) 0.03e1.7 0.44 9.88 10.7 0.28 [0.23e0.33] 0.56 [0.53e0.59]
C3M (ng/ml) 0.9e54 6.91 11.6 3.95 17.9 [15.7e20.0] 45.2 [42.0e48.4]
CRPM: MMP-derived degradation of CRP. C1M: MMP-mediated degradation of type I collagen. C2M: MMP-mediated degradation of type II collagen. C3M: MMP-mediated
degradation of type III collagen. n.a: not available. Reference values are inmean with 95% CI. The reference value of healthy young adults is the values stated in the kit protocol.
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predict radiographic progression over 1 year in RA patients27.
The previously described C2M ELISA detects an MMP-9-derived
fragment of type II collagen. The assay recognises the neo-epitope
GPPGRDGAAGY at position 1044e1053 and has shown to be neo-
epitope speciﬁc, as the assay does not recognise intact type II and
III collagen or MMP-cleaved type III collagen17. The level of C2M has
shown to be highly increased in both AS patients as well as RA
patients compared to controls2,28.
C3M is a previously described ELISA detecting an MMP-9-
derived fragment of type III collagen16,29,30. The neo-epitope of
the assay isYKNGETGPQGP at amino acid position 610e619 and the
assay has been biologically validated in several animal models of
ﬁbrosis in both serum and urine29e31. Furthermore, the monoclonal
antibody has shown only to recognize MMP-9 cleaved type III
collagen and not intact type III collagen, other collagens, or the
products of other proteinase-mediated collagen degradation16.
An ELISA detecting a degradation fragment of CRP derived from
MMP-1, -3, -8 and -9 cleavage has previously been described9. The
neo-epitope of the assay is YKAFVFPKESD at amino acid position
25e34 and has shown to be speciﬁc for this fragment, as it does not
recognise other protease cleavages of CRP, intact CRP or other
proteins. This fragment has shown to be elevated in AS patients
compared to controls28 and shown to be dose-dependently
decreased by an anti-IL-6 intervention2.
Brieﬂy, all ELISA was conducted as following; Streptavidin
coated plates were incubated with 100 ml biotinylated-peptide for
30 min at 20C. Plates were then washed ﬁve times in washing
buffer (20 nM TRIS, 50 mM NaCl, pH 7.2). Sample/standard/control
(20 ml) was added and followed immediately by addition of 100 ml
monoclonal antibody. This was incubated for 1 h at 20C (C3M and
CRPM) or ON at 4C (C1M and C2M). After incubation plates were
washed ﬁve times in washing buffer. A volume of 100 ml 3,30,5,50-
Tetramethylbenzidine was added and incubated for 15 min at 20C
in the dark. To stop the enzyme reaction of 3,30,5,50-Tetrame-
thylbenzidine, 100 ml 0.1% sulphuric acid was added. The enzyme
reaction was then read on an ELISA reader. Each ELISA plate
included both kit control and in-house quality control samples for
monitoring inter-assay variation (Table I).Table II
Mean level of clinical parameters with the grade of OA
Sex Age BMI
Male / Female Mean 95% CI Mean 95% CI
Mild 8/4 60.1 (54.5-65.6) 26.3 (24.2-28.4)
Moderate 92/110 64.4 (63.3-65.4) 27.8 (27.3-28.4)
Severe 28/29 65.6 (63.6-67.6) 29.4 (28.1-30.7)
TKR 27/33 69.1 (66.3-71.9) 29.7 (28.4-31.0)
BMI: Body mass index. One-way ANOVA analysis (Tukey’s multiple comparison 
test) was used. 
P=
0.
00
4
P=
0.
00
1
P=
0.
00
2
P=
0.
00
5To quantify the systemic level of inﬂammation, hsCRP (Siemens
74701) was used and measured on an Advia 1800 as stated by the
manufacture. The assay includes a suspension of uniform poly-
styrene latex particles coated with anti-CRP antibody. When serum
containing CRP was mixed with the latex reagent, agglutination
took place resulting in an increase in turbidity. This turbidity was
measured at 571 nm and the concentration of CRP was calculated
from a calibration curve that was generated by calibrators.
An overview of the technical performance of all assays is listed
in Table I. For all biomarkers a reference level of healthy adults as
stated in the kit protocols was used as reference level, in order to
investigate the OA level of the biomarkers in relation to healthy
level9,16e18. A reference level of RA patients for all biomarkers was
taken from a previous clinical study in order to investigate the
biomarker levels in relation to a highly joint inﬂamed group28.
Statistics
Summary statistics were used to generate Table II. Statistical
analysis was performed using one-way analysis of variance analysis
(ANOVA) with a Tukey post hoc test to test for difference between
multiple comparisons of log-transformed biomarkers, when pa-
tientsweredividedbyKL scoreor groupedby inﬂammation level. All
observations were independent, but as the biochemical markers
were not normally distributed and due to unequal standard de-
viations the data was log-transformed before ANOVA. By log-
transformation the biochemical marker data became moderately
normally distributed and Gaussian distribution was therefore
assumed. Area under the curve (AUC) receiver operator character-
istics (ROC)wasused tocalculate cut-off value forCRPM.Theoptimal
cut-off for CRPM for TKR patients vs C4Pain patients with KL 3 and 4
(controls) was determined by ROC and discriminationwas assessed
by AUC analysis and peak likelihood ratio was selected as cut-off
value. These groups were chosen due to the similarity between the
groups in age, gender, BMI andKL, but a difference in bothhsCRPand
CRPM level (Table II, Fig. 1). This highest likelihood ratio calculated
from AUC ROC was chosen with a corresponding value of CRPM of
12.7 ng/mL. CRPMhad a sensitivity of 62.1 and a speciﬁcity of 84.6 at
a likelihood ratioof 4.0. The cut-off value of hsCRPwas set asmeanof
reference level þ 2SD to 5 mg/mL.
All values are presented as mean and 95% CI if not otherwise
stated and were considered statistical signiﬁcance for P < 0.05. All
statistical analysis was performed in GraphPad Prism 6.
Results
Association between KL score and the biochemical markers
Patients were divided into four groups dependent on their KL
score and whether they had been referred to TKR. There was no
marked difference in the gender distribution across the groups: The
percentage of womenwas 33% inMild OA, 54% inModerate OA, 49%
in Severe OA and 55% in TKR (See Table II). Patients referred to TKR
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Moderate OA (P ¼ 0.001), but not Severe OA (Table II). BMI was
signiﬁcantly higher in TKR compared to Mild (P ¼ 0.002) and
Moderate OA (P ¼ 0.005). hsCRP was signiﬁcantly elevated in TKR
compared to Mild (P ¼ 0.003) and Moderate OA (P < 0.001)
[Fig. 1(A)]. The CRPM level was signiﬁcantly higher in TKR
compared to Moderate OA (P ¼ 0.003; [Fig. 1(B)]). There were
highly signiﬁcant elevations in C1M level in the TKR compared to
Moderate (P < 0.001) and Severe OA (P ¼ 0.003) [Fig. 1(C)]. C2M
was signiﬁcantly elevated in TKR compared toModerate (P< 0.001)
and Severe OA (P < 0.001; [Fig. 1(D)]). There was no signiﬁcant
difference in the C3M level between any of the groups [Fig. 1(E)].
Interestingly, there was no signiﬁcant difference in any of the
markers between Mild, Moderate or Severe OA.
Segregation and characterization of patient groups based on levels
of hsCRP and CRPM
Fig. 2(A) shows a likelihood plot of hsCRP, where it is evident
that 5 mg/mL has not the highest likelihood ratio. However, based
on the sensitivity and speciﬁcity listed in the table of Fig. 2(B), the
cut-off value of 5 mg/mL was selected, as it has the highest sensi-
tivity of 33.3, though lowest speciﬁcity of 87.18. A cut-off value of
12.7 ng/mL for CRPM was determined by ROCs at the highest
likelihood ratio, when plotting TKRs against the Severe OA group.
Patients were segregated into quadrants (Q) based on the cut-off
values [Fig. 2(C)]: 232 (69%) of patients were low in both markers
(Q1); 45 (13%) of the patients were low in hsCRP and high in CRPM
(Q2); 41 (12%) were high in hsCRP and low in CRPM (Q3); and 19
(6%) were high in bothmarkers (Q4). The percentage of womenwas
52% in Q1, 42% in Q2, 68% in Q3 and 47% in Q4. There was no dif-
ference in mean age between the groups, but Q4 had signiﬁcantly
higher BMI than Q1 (P ¼ 0.013; Table III). The KL score was signif-
icantly higher in Q3 compared to Q1 (P ¼ 0.001) and Q2 (P< 0.001;
[Fig. 3(A)]).
Therewas an association between hsCRP and the level of C1M as
patients with high hsCRP had high C1M [Fig. 3(B)]. Firstly, patients
of Q1 had a signiﬁcant lower level of C1M compared to Q3 and Q4
(P < 0.001). Secondly, C1M level was higher in Q4 compared to Q2
(P < 0.001). Lastly, C1M was higher in Q3 compared to Q2Fig. 1. Biomarker level depending on grade of OA and in the group scheduled for TKR. Mild:
referred to TKR; KL 3 and 4, n ¼ 60. A: Systemic CRP level detected by hsCRP (mg/mL). B: M
collagen quantiﬁed by C1M18. D: MMP-derived degradation of type II collagen quantiﬁed b
depicted as mean þ 95% CI and one-way ANOVA (Tukey’s multiple comparison test) was u(P < 0.001). There was a signiﬁcant difference in C2M between Q2
and Q3 (P ¼ 0.03; [Fig. 3(C)]). C3M was signiﬁcantly elevated in Q4
compared to Q1 and Q3 (P < 0.001 and P ¼ 0.001, respectively;
[Fig. 3(D)]). Moreover, the C3M level was higher in Q2 compared to
Q1 (P < 0.001).
Discussion
It is recognized that inﬂammation is a contributing factor in OA
pathology4,10, but little is known about how the level of inﬂam-
mation is related to OA severity and tissue destruction. The pri-
mary aim of the study was to describe the structural integrity of
OA patients segregated by the level of systemic (hsCRP) and/or
MMP-derived inﬂammation (CRPM). We found that when pa-
tients were divided based on hsCRP and CRPM, the structural
integrity was signiﬁcantly different between the four groups,
indicating several distinctively subpopulations of OA patients.
When segregating patients based on stage of OA (KL) and referral
to TKR, we found that patients referred to TKR had higher
inﬂammation level and degradation of type I and III collagen (C1M
and C3M, respectively). However, this could be due to the con-
founding factors (age and BMI) that were not accounted for in the
analysis.
Pro-inﬂammatory cytokines, such as IL-6, IL-1 and tumour
necrosis factor-a (TNF-a), are believed to play major roles in the
development of OA. They are not only expressed in the cartilage,
but also in the surrounding joint tissue (e.g., bone and syno-
vium)32e34. Elevated levels of IL-1, TNF-a and especially IL-6 lead
to the production of the acute phase protein CRP by hepatocytes7.
CRP is one of the only biomarkers to quantify inﬂammation, but it
quantiﬁes systemic inﬂammation and may therefore not resemble
the disease related chronic tissue inﬂammation. It is speculated
that CRP may be processed by tissue related proteases, when
coming in contact with its receptor. CRPM is a degradation product
of CRP, which has been shown to be released through MMP-
activity and thus may reﬂect tissue related CRP degradation. The
difference between CRP and CRPM as biomarkers of inﬂammation
was illustrated in a study of RA patients, where patients received
an IL-6 intervention. The CRP level dropped dramatically to w5%
of the baseline level after 2 weeks of treatment and stayed at thatKL 0, n ¼ 12. Moderate: KL 1 and 2, n ¼ 204. Severe: KL 3 and 4, n ¼ 158. TKR: Patients
MP-derived inﬂammation quantiﬁed by CRPM9. C: MMP-derived degradation of type I
y C2M17. E: MMP-derived degradation of type III collagen quantiﬁed by C3M16. Data is
sed to test for signiﬁcance. Biomarker data was log-transformed before analysis.
Fig. 2. Likelihood plot and table of values of hsCRP and the segregation of patients based on the cut-offs of hsCRP and CRPM. A: Likelihood plot of hsCRP (mg/mL). B: Table of the
highest likelihood ratios, with concomitant sensitivity, speciﬁcity and hsCRP level. C: Correlation plot of hsCRP and CRPM, with cut-off to divide patients into four categories: Q1:
Low systemic and MMP-derived inﬂammation; Q2: Low systemic inﬂammation and high MMP-derived inﬂammation; Q3: High systemic inﬂammation and low MMP-derived
inﬂammation; Q4: High systemic and MMP-derived inﬂammation. Filled triangles: Patients referred to TKR. Open circles: Patients not referred to TKR. CRPM: MMP-derived
inﬂammation quantiﬁed by MMP-derived degradation of CRP.
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level only decreased by 1/3 after 2 weeks, but kept decreasing
with time2.
In the current study we show that less than 18% of the OA
population had markedly increased hsCRP levels and approxi-
mately 19% of the OA patients had MMP-derived inﬂammation in
line with previous data showing that 25% experience synovitis3,4.
The overlap between the two inﬂammation groups was 18%
[Fig. 2(C)]. This indicates that the population selected by the
different inﬂammation markers resembles different OA pop-
ulations. A subpopulation of acute inﬂamed OA patients is selected
by hsCRP and a different subpopulation with MMP-derived
inﬂammation is selected by CRPM. This is supported by the fact
that synovitis is an established component of RA, but it is infre-
quently observed in OA35. These observations underline that not all
OA patients could have beneﬁt from one of the several anti-
inﬂammatory interventions (anti-IL-1b, anti-IL-6 and anti-TNF-a)
already in use in RA and AS, due to the possible lack of tissue
inﬂammation in most patients. Thus, there is a need for selecting
the OA patients with tissue inﬂammation in order to investigate if
anti-inﬂammatory treatments could beneﬁt this OA subpopulation.
Another important difference between RA and OA is themassive
systemic and poly-articular inﬂammatory nature of RA and the
joint speciﬁc uni-articular inﬂammation in OA. Thus, it is expected
that the inﬂammatory load in RA is much higher than in OA
resulting in continuously higher levels of hsCRP in RA patients.
However, even lower levels of local inﬂammation give rise in CRP,Table III
Mean level of clinical parameters in quartiles by inﬂammation
Sex Age BMI
Male / Female Mean 95% CI Mean 95% CI
Q1 111/121 65.0 (63.9-66.0) 27.9 (27.4-28.4)
Q2 26/19 64.7 (62.1-67.3) 28.2 (27.0-29.4)
Q3 13/28 67.8 (64.9-70.7) 29.7 (27.9-31.5)
Q4 10/9 66.3 (62.0-70.5) 31.0 (28.2-33.8)
BMI: Body mass index. One-way ANOVA analysis (Tukey’s multiple 
comparison test) was used. 
P=
0.
01
3which may not always be measurable by standard techniques.
Degradation products of CRP could be possible markers of chronic
tissue inﬂammation, but this have to be conﬁrmed by future
biomarker development and studies. The CRPM fragment level was
elevated in all OA severity groups compared to the healthy adult
reference range, showing that the inﬂammatory burden was in-
dependent of disease severity (KL score). The levels of type II and III
collagen degradation (C2M and C3M) were higher in the subpop-
ulation with high MMP-derived inﬂammation (Q2) compared to
the population with only high acute inﬂammation (Q3), suggesting
that cartilage and joint destruction is associated with a speciﬁc
phenotype. In contrast the subpopulation with high acute CRP had
a higher turnover of type I collagen compared to the subpopulation
with high MMP-derived inﬂammation. These data indicate that
turnover of type I collagen is somewhat associated to peripheral
inﬂammation, whereas joint tissue integrity, measured by C2M and
C3M, is associated with focal inﬂammation. However, it is still
speculative if C2M originates from cartilage as this has never been
fully proven in in vivo studies, but as type II collagen is almost
exclusively in cartilage it most properly originates from cartilage.
The origin of C3M is still to be determined. In summary, this study
illustrates that the OA population is a diverse disease population
with distinct subpopulations based on CRP, and CRPM and C1M,
C2M and C3M. This illustrates that MMP-mediated degradation of
type I, II and III collagen is increased with inﬂammation and the
different inﬂammatory subpopulations have different structural
integrity.
There are several limitations in this study. Firstly, the OA pa-
tients considered themselves as otherwise healthy and had no
symptoms or diagnosis of ﬁbrotic disease or inﬂammatory diseases.
However, the markers C1M and C3M have previously been shown
to be elevated in lung and liver ﬁbrosis, as they are marker of the
most abundant proteins of connective tissues which are widely
affected by ﬁbrotic diseases29e31. Needless to say that it is impos-
sible to correct for undiagnosed diseases. Secondly, in the statistical
analysis we did not correct for possible confounders, such as age,
sex and BMI. These confounders are known to affect hsCRP and
could possible affect the other biomarkers as well. Lastly, the
studies were from two sites, hence the handling of the serum could
have been different, even though the studies followed the same
Fig. 3. Grade of OA and destructive collagen biomarkers in the four OA populations based of systemic (hsCRP) and MMP-derived inﬂammation (CRPM) described in Fig. 2. A: KL
level in the four quadrants. B: C1M level in the four quadrants. C: C2M level in the four quadrants. D: C3M level in the four quadrants. The quadrants refer to the quadrants in
Fig. 2(C) and there are 232 patients in Q1, 45 in Q2, 41 in Q3 and 19 in Q4. Data are depicted as mean þ 95% CI. One-way ANOVA (Tukey’s multiple comparison test) was used to test
for signiﬁcance.
A.S. Siebuhr et al. / Osteoarthritis and Cartilage 22 (2014) 44e50 49shared protocol. This difference in handling could be inﬂuencing on
the results, which showed that TKR was higher in most of the
markers compared to Mild, Moderate and Severe OA determined by
KL. However, during the biomarker development shared kit control
and quality control samples were used to investigate the inter-
assay variability on each plate.
In conclusion, we found that OA patients differ and several
structurally distinctively different subpopulations can be selected
based on acute and MMP-dependent inﬂammation. We suggest
that OA patients are segregated into several subpopulations before
treatment initiation, due to the heterogeneity of the disease
population.
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